

BIOCRYST PHARMACEUTICALS INC

Form 8-K

April 21, 2005

---

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: April 21, 2005**

**BioCryst Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**000-23186**  
(Commission File Number)  
**2190 Parkway Lake Drive, Birmingham, Alabama 35244**  
(Address of Principal Executive Office)

**62-1413174**  
(IRS Employer Identification #)

**(205) 444-4600**  
(Registrant's telephone number, including area code)

---

**Item 2.02. Results of Operations and Financial Condition:**

On April 21, 2005, the Company issued a news release announcing its financial results for the quarter ended March 31, 2005, which also referenced a conference call to discuss these results and provide an update on the status of the Company's programs. A copy of the news release is furnished as exhibit 99.1 hereto and is incorporated by reference into Item 9.01 of Form 8-K.

**Item 9.01. Financial Statements and Exhibits:**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated April 21, 2005 entitled BioCryst Reports First Quarter 2005 Financial Results

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 21, 2005

BIOCRYST PHARMACEUTICALS, INC.

By:   /s/ MICHAEL A. DARWIN

**Michael A. Darwin**  
**Chief Financial Officer and Chief**  
**Accounting Officer**

**EXHIBIT INDEX**

<b>Item</b>	<b>Description</b>
99.1	Press release dated April 21, 2005 entitled BioCryst Reports First Quarter 2005 Financial Results